Moser, Stephan; Rehm, Sophia; Guertler, Nicolas; Hinic, Vladimira; Dräger, Sarah; Bassetti, Stefano; Rentsch, Katharina M; Sendi, Parham; Osthoff, Michael (2021). Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs. The journal of antimicrobial chemotherapy, 76(7), pp. 1845-1854. Oxford University Press 10.1093/jac/dkab089
|
Text
dkab089.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (590kB) | Preview |
OBJECTIVES
MSSA bloodstream infections (BSIs) are associated with considerable mortality. Data regarding therapeutic drug monitoring (TDM) and pharmacological target attainment of the β-lactam flucloxacillin are scarce.
PATIENTS AND METHODS
We determined the achievement of pharmacokinetic/pharmacodynamic targets and its association with clinical outcome and potential toxicity in a prospective cohort of 50 patients with MSSA-BSI. Strain-specific MICs and unbound plasma flucloxacillin concentrations (at five different timepoints) were determined by broth microdilution and HPLC-MS, respectively.
RESULTS
In our study population, 48% were critically ill and the 30 day mortality rate was 16%. The median flucloxacillin MIC was 0.125 mg/L. The median unbound trough concentration was 1.7 (IQR 0.4-9.3), 1.9 (IQR 0.4-6.2) and 1.0 (IQR 0.6-3.4) mg/L on study day 1, 3 and 7, respectively. Optimal (100% fT>MIC) and maximum (100% fT>4×MIC) target attainment was achieved in 45 (90%) and 34 (68%) patients, respectively, throughout the study period. Conversely, when using the EUCAST epidemiological cut-off value instead of strain-specific MICs, target attainment was achieved in only 13 (26%) patients. The mean unbound flucloxacillin trough concentration per patient was associated with neurotoxicity (OR 1.12 per 1 mg/L increase, P = 0.02) and significantly higher in deceased patients (median 14.8 versus 1.7 mg/L, P = 0.01).
CONCLUSIONS
Flucloxacillin pharmacological target attainment in MSSA-BSI patients is frequently achieved when unbound flucloxacillin concentrations and strain-specific MICs are considered. However, currently recommended dosing regimens may expose patients to excessive flucloxacillin concentrations, potentially resulting in drug-related organ damage.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases > Research 04 Faculty of Medicine > Service Sector > Institute for Infectious Diseases |
UniBE Contributor: |
Sendi, Parham |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
1460-2091 |
Publisher: |
Oxford University Press |
Language: |
English |
Submitter: |
Parham Sendi |
Date Deposited: |
03 Dec 2021 15:18 |
Last Modified: |
05 Dec 2022 15:54 |
Publisher DOI: |
10.1093/jac/dkab089 |
PubMed ID: |
33860325 |
BORIS DOI: |
10.48350/160697 |
URI: |
https://boris.unibe.ch/id/eprint/160697 |